Assignee
HEPTARES THERAPEUTICS LTD
GB·78 granted patents·23 pending applications·735 citations·filing 2012–2023
Top patents by PatentIndex Score
101 records- 0198US11352342B2Pharmaceutical compoundsHEPTARES THERAPEUTICS LTD·Filed 2020·Granted Jun 7, 2022·9 cites·10 claims
- 0298US11254656B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2020·Granted Feb 22, 2022·10 cites·10 claims
- 0398US11014880B2Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2020·Granted May 25, 2021·9 cites·13 claims
- 0498US10961225B2Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptorHEPTARES THERAPEUTICS LTD·Filed 2020·Granted Mar 30, 2021·11 cites·16 claims
- 0598US9670183B2Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2015·Granted Jun 6, 2017·34 cites·23 claims
- 0697US11834407B2Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2021·Granted Dec 5, 2023·5 cites·13 claims
- 0797US11773090B2Pharmaceutical compoundsHEPTARES THERAPEUTICS LTD·Filed 2020·Granted Oct 3, 2023·6 cites·10 claims
- 0897US11319312B2Pharmaceutical compoundsHEPTARES THERAPEUTICS LTD·Filed 2020·Granted May 3, 2022·10 cites·20 claims
- 0997US10973832B2Muscarinic M1 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Apr 13, 2021·10 cites·16 claims
- 1097US10689368B2Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptorHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Jun 23, 2020·12 cites·20 claims
- 1197US10329278B2Pharmaceutical compoundsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Jun 25, 2019·13 cites·17 claims
- 1297US10196380B2Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Feb 5, 2019·20 cites·16 claims
- 1396US11680053B2Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulatorsHEPTARES THERAPEUTICS LTD·Filed 2021·Granted Jun 20, 2023·2 cites·22 claims
- 1496US11584732B2Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulatorsHEPTARES THERAPEUTICS LTD·Filed 2021·Granted Feb 21, 2023·4 cites·17 claims
- 1596US11091456B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Aug 17, 2021·10 cites·20 claims
- 1696US11034704B2Muscarinic receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Jun 15, 2021·10 cites·13 claims
- 1796US10981889B24-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulatorsHEPTARES THERAPEUTICS LTD·Filed 2020·Granted Apr 20, 2021·5 cites·12 claims
- 1896US10759751B2Substituted spirocyclohexanes as muscarinic M1 receptor and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Sep 1, 2020·12 cites·18 claims
- 1996US10752610B2Pharmaceutical compoundsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Aug 25, 2020·10 cites·20 claims
- 2096US10259787B2Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted Apr 16, 2019·13 cites·8 claims
- 2196US9926297B2Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted Mar 27, 2018·19 cites·18 claims
- 2296US9758506B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Sep 12, 2017·22 cites·20 claims
- 2396US9260505B2Methods for screening for binding partners of G-protein coupled receptorsHEPTARES THERAPEUTICS LTD·Filed 2014·Granted Feb 16, 2016·104 cites·20 claims
- 2495US11999745B2Pharmaceutical compoundsHEPTARES THERAPEUTICS LTD·Filed 2022·Granted Jun 4, 2024·3 cites·31 claims
- 2595US10548884B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Feb 4, 2020·11 cites·17 claims
- 2695US10385039B2Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Aug 20, 2019·13 cites·20 claims
- 2795US9907805B2Muscarinic M1 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted Mar 6, 2018·15 cites·10 claims
- 2894US12024499B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2022·Granted Jul 2, 2024·2 cites·7 claims
- 2994US10413553B2Muscarinic M1 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Sep 17, 2019·11 cites·8 claims
- 3094US10030035B2Muscarinic receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2015·Granted Jul 24, 2018·14 cites·17 claims
- 3194US9669013B2Bicyclic aza compounds as muscarinic M1 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Jun 6, 2017·14 cites·18 claims
- 3294US9573929B2Muscarinic M1 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2015·Granted Feb 21, 2017·12 cites·4 claims
- 3394US9266857B2Bicyclic AZA compounds as muscarinic M1 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2013·Granted Feb 23, 2016·23 cites·14 claims
- 3493US10738029B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Aug 11, 2020·12 cites·6 claims
- 3593US10428088B2Muscarinic receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Oct 1, 2019·11 cites·10 claims
- 3693US10351545B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted Jul 16, 2019·10 cites·30 claims
- 3793US10246432B24-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulatorsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted Apr 2, 2019·9 cites·12 claims
- 3893US10167272B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Jan 1, 2019·11 cites·21 claims
- 3993US10112923B21,2,4-triazine-4-amine derivativesHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Oct 30, 2018·20 cites·3 claims
- 4093US9975890B2Bicyclic AZA compounds as muscarinic M1 receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted May 22, 2018·10 cites·9 claims
- 4193US9187451B2Muscarinic M1 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2012·Granted Nov 17, 2015·15 cites·14 claims
- 4292US10858352B2Pharmaceutical compoundsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Dec 8, 2020·11 cites·20 claims
- 4392US10787447B2Pharmaceutical compoundsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Sep 29, 2020·11 cites·18 claims
- 4492US10584111B24-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulatorsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Mar 10, 2020·7 cites·15 claims
- 4592US10259802B2Bicyclic aza compounds as muscarinic M1 receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Apr 16, 2019·9 cites·20 claims
- 4691US11324738B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted May 10, 2022·9 cites·18 claims
- 4791US11208396B2Oxime compounds as agonists of the muscarinic M1 and/or M4 receptorHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Dec 28, 2021·9 cites·16 claims
- 4891US10167284B2Spirocyclic compounds as agonists of the muscarinic M1 receptor and/or M4 receptorHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Jan 1, 2019·12 cites·20 claims
- 4991US9676745B24-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulatorsHEPTARES THERAPEUTICS LTD·Filed 2014·Granted Jun 13, 2017·10 cites·9 claims
- 5091US9593106B2Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2014·Granted Mar 14, 2017·20 cites·12 claims
Showing the top 50 of 101 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →